General pathophysiology LIPID METABOLISM

Similar documents
1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?

Plasma lipoproteins & atherosclerosis by. Prof.Dr. Maha M. Sallam

Lipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry

Lipids digestion and absorption, Biochemistry II

Lipid metabolism in familial hypercholesterolemia

Hyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi

Pathophysiology of Lipid Disorders

Lipid/Lipoprotein Structure and Metabolism (Overview)

Cholesterol and its transport. Alice Skoumalová

Part 1 Risk Factors and Atherosclerosis. LO1. Define the Different Forms of CVD


Arteriosclerosis & Atherosclerosis

LIPID METABOLISM. Sri Widia A Jusman Department of Biochemistry & Molecular Biology FMUI

Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins

PLASMA LIPOPROTEINS AND LIPIDS DETERMINATION OF PLASMA CHOLESTEROL AND TRIGLICERIDE LEVEL

High density lipoprotein metabolism

ANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism

Topic 11. Coronary Artery Disease

Anti Hyperlipidemic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Incorporating HDL interaction in an ODE model of Atherosclerosis

Chapter VIII: Dr. Sameh Sarray Hlaoui

Lipoproteins Metabolism


ANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD

Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD

Cholesterol metabolism. Function Biosynthesis Transport in the organism Hypercholesterolemia


THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS

Antihyperlipidemic drugs

BIOL2171 ANU TCA CYCLE

Cholesterol Metabolism

CHAPTER FORTY FIVE ENDOGENOUS LIPID TRANSPORT PATHWAY: VLDL AND IDL

Dyslipidemia Endothelial dysfunction Free radicals Immunologic

Antihyperlipidemic Drugs

Lipid Metabolism Prof. Dr. rer physiol. Dr.h.c. Ulrike Beisiegel

Hypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002

BIOB111_CHBIO - Tutorial activity for Session 12

Lipid Metabolism in Familial Hypercholesterolemia

STRUCTURE AND METABOLISM Of LIPIDS AND LIPOPROTEINS. R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty

Lipid Lowering Drugs. Dr. Alia Shatanawi

13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids:

PPAR history of research

Leptin deficiency suppresses progression of atherosclerosis in apoe-deficient mice

ATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS

By: Dr Hadi Mozafari 1

Oxidation of Long Chain Fatty Acids

Pathology of Coronary Artery Disease

Podcast (Video Recorded Lecture Series): Lipoprotein Metabolism and Lipid Therapy for the USMLE Step One Exam

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk

METABOLISM of ADIPOSE TISSUE

Cholesterol and Cholesterol Oxides on Coronary Heart Diseases

Health and Disease of the Cardiovascular system

N-3 Fatty Acids Non-HDL-Cand LDL-C Thomas Dayspring MD, FACP

ANSC/NUTR 618 LIPIDS & LIPID METABOLISM The LDL Receptor, LDL Uptake, and the Free Cholesterol Pool

Dyslipidemia. Team Members: Laila Mathkour, Khalid Aleedan, Bayan Al-Mugheerha, Fatima AlTassan

determination of Triglyceride in Serum Amal Alamri

A Review: Atherosclerosis & its treatment

BCM 221 LECTURES OJEMEKELE O.

2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries

Imbalances in lipid components

Cellular control of cholesterol. Peter Takizawa Department of Cell Biology

Bio 366: Biological Chemistry II Test #1, 100 points (7 pages)

Metabolism of acylglycerols and sphingolipids. Martina Srbová

DYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Cholesterol (blood, plasma, serum)

Objectives By the end of lecture the student should:

Investigations on the mechanism of hypercholesterolemia observed in copper deficiency in rats

Integration Of Metabolism

Triglyceride determination

Biochem. q1) the amount of cholesterol lost per day is: +a.1g/day b.10g/week c.15g/day d.5g/day

CHM333 LECTURE 34: 11/30 12/2/09 FALL 2009 Professor Christine Hrycyna

Introduction Hyperlipidemia hyperlipoproteinemia Primary hyperlipidemia (Familial) Secondary hyperlipidemia (Acquired)

Chapter (5) Etiology of Low HDL- Cholesterol

Chapter 24 Cholesterol, Energy Balance and Body Temperature. 10/28/13 MDufilho

Niacin Metabolism: Effects on Cholesterol

Lipids: Lipid functions: Classification of lipids:

Adipose Tissue as an Endocrine Organ. Abdel Moniem Ibrahim, MD Professor of Physiology Cairo University

Antihyperlipidemic Drugs

Regulating Hepatic Cellular Cholesterol

Thematic review series: The Immune System and Atherogenesis

Cholesterol, Heart Attack and Stroke. Dr Tai E Shyong Consultant Department of Endocrinology Singapore General Hospital

Nutrition & Wellness for Life 2012 Chapter 6: Fats: A Concentrated Energy Source

Lipids Definition. Definition: Water insoluble No common structure (though generally large R groups)

Definition: Water insoluble No common structure (though generally large R groups)

Moh Tarek + Suhayb. Tamara Al-Azzeh + Asmaa Aljeelani ... Faisal

Estimation of glucose in blood serum

Lipid Metabolism. Remember fats?? Triacylglycerols - major form of energy storage in animals

Lipid Metabolism * OpenStax

ATHEROSCLEROSIS زيد ثامر جابر. Zaid. Th. Jaber

Metabolic integration and Regulation

Integration Of Metabolism

ANSC/NUTR 601 GENERAL ANIMAL NUTRITION Stearoyl-CoA desaturase, VLDL metabolism, and obesity

Nutrition, Food, and Fitness. Chapter 6 Fats: A Concentrated Energy Source

23.1 Lipid Metabolism in Animals. Chapter 23. Micelles Lipid Metabolism in. Animals. Overview of Digestion Lipid Metabolism in

Dr G R Letchuman. Clogged by Cholesterol

GLOSSARY Saturated Fatty Acids (SFA) Unsaturated Fatty Acids (UFA) Monounsaturated Fatty Acids (MUFA) Polyunsaturated Fatty Acids (PUFA) Cis

Organic molecules highly hydrophobic and water insoluble.

KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers

Nature Genetics: doi: /ng.3561

Transcription:

General pathophysiology LIPID METABOLISM 1. Alimentary chylomicronemia is sustained in: 1. Lipoprotein lipase deficiency. 2. Inhibited lipoprotein lipase. 3. Hypoalbuminemia. 4. Hyperalbuminemia. 2. Direct source of LDL are: 1. VLDL. 2. IDL. 3. HDL. 4. VLDL and HDL. 5. Chylomicrones. 3. The main pathogenic factor for atherosclerosis is: 1. Blood hyper-ldl. 2. Blood hyper-vldl. 3. Blood hypo-hdl. 4.Hyperproteinemia. 5. Hypercoagulation. 4. The main reason for the atherogenic effects of LDL is: 1. Their cholesterol ester content 2. Their TriAcylGlycerols (TAGs) content. 3. Their oxidized form(oxy-ldl) 4. Their protein component. 5. Their phospholipids content. 5. The main reason for the atherogenic effects of oxy-ldl is their ability to: 1. Form interplatelet bounds. 2. Damage the endothelial membrane. 3. Stimulate macrophagephagocytosis in subendothelium. 4. Induce dysproteinemia. 5. 2, 3. 6. Macrophages are capable of phagocyting oxy-ldl due to: 1. Chemotactic factors 2. Lipid peroxides produced subendothelially by the arterial wall intimal layer. 3. Specific receptors for oxy-ldldetection 4. Cytokines produced by the arterial wall intima.

5. 1, 2, 4. 7. Foam cells are: 1.Specialized cleaning LDL-macrophages. 2. Transformed endothelial cells. 3. Fixed multinucleate cells. 4. Activated multipotent cells. 5. Modified platelets. 8. Where does atherosclerotic plaque develop? 1. In the subendothelial space of the arterial wall. 2. In the medial layer of the arterial wall. 3. Bellow the medial layer of the arterial wall. 4. Bellow the adventitious layer of the arterial wall 5. In the adventitious layer of the arterial wall. 9. Reversibility of theatheroscleroticplaqueis determined mainly by: 1. The presence of Foam cells 2. The presence of smooth muscle cells. 3. The presence of extracellular collagen 4. Platelet adhesion. 5. Plaque capillarization. 10. Conditions for ketonemia are: 1Increased mobilizationof the free fatty acids (FFA) from fat depots. 2. Depressed beta-oxidation in the muscles 3. Krebs cycle activation in the liver. 4. β-hydroxy-β-methylglutaryl CoAcycle activationin the liver. 5. 1, 4. 6. 1, 2, 3. 11. Which plasma lipid constellation represents the highest atherogenic risk? 1. Hyperchylomicronemiaand hypohdl-lipoproteinemia. 2. HyperLDL and hyperhdl lipoproteinemia. 3. Hyper VLDL, LDL andhdl lipoproteinemia. 4. HyperLDL and hypo HDL lipoproteinemia 5. HypoHDL and hypoldl lipoproteinemia. 12. In pathophysiologic aspect obesity is divided into: 1. Hypertrophicandatrophic obesity 2. Aplastic, hypoplasticandhyperplastic obesity 3. Obesity with increased volume of fat, decreased volume of fat and with disturbed fat distribution. 4. Alimentary, regulatory andmetabolic obesity.

5. Alimentary obesity, obesity due to decreased physical activity, hereditary obesity. 13. Hyperinsulinemia leads to obesity by: 1. Stimulatingthe production ofglycerol-3-phosphate. 2. Pentosecycle (NADPH 2 ) activation. 3. IncreasedacetylCoA synthesis. 4. Inhibiting the activityofhormone-sensitive lipase. 5. 1, 2, 4. 6. 1, 2, 3, 4. 14. Blocked VLDL fromation in the liver leads to: 1. Cirrhosis 2. Lipid dystrophy 3. Hemochromatosis 4. Hepatocytic regeneration. 5. Hepatocytic apoptosis. 15. VLDLsynthesis in the hepatocytes is impaired in: 1. Suppressed apoprotein synthesis. 2. Lipid/apoprotein decomposition. 3. Impaired VLDL- secretion. 4. Lipid(TG, PhL, Cholesterol)synthesis dissociation in hepatocytes. 16. Which hormone ratio determines liver ketogenic potential: 1Glucocorticosteroids/thyroxine. 2. Glucagon/insulin. 3. Tropichormones/somatomedin. 4. Catecholamines/glucocorticosteroids. 5. Renin/plasmin. 17. Ketonemiais a manifestation of: 1. Increasedketogenesisin the liver. 2. Keto-production from adipocytes. 3. Suppressedextrahepaticketolysis. 4. Blockedhepaticketolysis. 5. 1, 3. 18. Receptor-independent pathway of eliminationof plasmaldlismainly presentedin: 1.Adipocytes. 2. Fibrocytes. 3. Mononuclear phagocyte system. 4. Myofibers. 5. Epithelium. 19. Which are the mechanisms that protect cells from accumulating cholesterol? 1. Own cholesterolsynthesis(hmg-coa reductase) inhibition.

2. Increasedesterificationof freecholesterol (AHA). 3. Hiding(decomposition) of LDL-receptors anddecreased synthesis 4. Increasedcholesterolexport contact with HDL3 6. 1, 3, 4 20. The antiatherogenic effect of HDL is associated with: 1. Adsorption, esterification and transport of cell cholesterol to the liver. 2. Inhibition of LDL oxidation. 3. Prolongation and enhancing the effects of prostacyclin. 4. Binding and inhibition of bacterial lipopolysaccharides 21. Mandatorytriggerofatherogenicvascular damageis: 1. Endothelialdysfunction. 2. Hyperlipoproteinemia. 3. Hyperuricemia. 4. Structuralvascular"injury - lesion. 5. Pericytes remodeling. 22. Atherogenicendothelial dysfunctionis associated with: 1. Increasedendothelialpermeability. 2. Reducedplateletresistance. 3. Increasedadhesionof blood cells. 4. 1, 2. 23. Endothelial dysfunction (caused by hyperlipoproteinemia) is a result of: 1. Increased endothelial membrane cholesterol. 2. Increasedrigidityof theendothelial cells. 3. Endothelialseparation andrestriction. 4. Increasedendothelialpermeability. 24. Exogenoushyperlipidemiais: 1. Hyper HDL lipoproteinemia. 2. Hyperchylomicronemia. 3. Hyper LDL lipoproteinemia. 4. Hyper VLDL lipoproteinemia. 5. Hyper IDL lipoproteinemia 25. Regarding the lipoprotein-lipase NaCl acts as a: 1. Cofactor. 2. Inhibitor. 3. Activator. 4. Signal modulator. 5. NaCl does not affect the activity of LPL.

26. How does hypoalbuminemia lead to hyperlipidemia? 1. Impaired LPL secretion. 2. Enhanced LPL. 3. Incompleteacceptanceof the releasedffa (free fat acids). 4. Impaired LPL binding to lipoproteins 5. Stabilizingthe structure ofchylomicrones. 27. Which is the inhibitor of LPL during cholestasis? 1. Bilirubin. 2. Bile salts. 3. ALP(alkaline phosphatase). 4. ASAT and ALAT. 5. Cholesterol. 28. Inadequateand /or delayedleptin secretionleads to: 1. Redistribution oftriglyceridesbetweenadipocytes. 2. Lossof triglyceridesfromadipocytes. 3. Appetite suppression. 4. Accumulation of triglyceridesin adipocytes. 5. Activationof thesatietycenter. 29. Secretion of leptin leads to: 1. Enhancedlipogenesis. 2. Directstimulation of lipolysis. 3. Regulation ofthe relationship betweenlipolysisandlipogenesis. 4. Activation ofhormone-sensitive lipase. 5. Stimulattion ofcatecholaminebeta-receptors. 30. The amountof leptinin the circulationcorrelateswith: 1. Physical capacity. 2. Adipose tissue volume. 3. Visceralorgans size. 4. Pituitarytropichormones. 5. Lipoproteins concentration. 31. What is the most characteristic behavior for Homo sapiens regarding obesity? 1. To controlhis foodbiorhythms. 2. To regulatesatiety. 3. To eatwithout beinghungry. 4. To eatwithoutchewing. 5. To stimulatehis sense ofhunger.